Selected menu has been deleted. Please select the another existing nav menu.
=

Centre proposes tighter antimicrobial regulation, Schedule M relief for select manufacturers

Lorem ipsum dolor sit amet consectetur. Facilisis eu sit commodo sit. Phasellus elit sit sit dolor risus faucibus vel aliquam. Fames mattis.

HTML tutorial

The Union Health Ministry has proposed bringing antimicrobial drugs under the regulatory framework for new drugs to strengthen quality checks amid growing concerns over antimicrobial resistance (AMR). It has also proposed exemptions from certain requirements under the revised Schedule M for manufacturers of empty gelatin capsules, medicinal gases and disinfectant fluids.The proposals have been outlined in two separate draft notifications seeking amendments to the New Drugs and Clinical Trials Rules, 2019, and the Drugs Rules, 1945.Under the first proposal, antimicrobials will be included in the definition of a ‘New Drug’. This would require manufacturers to obtain prior permission from the Central Licensing Authority (CLA) before approaching the respective State Licensing Authority (SLA) for a manufacturing licence.The proposed move follows concerns that manufacturing licences for antimicrobial products have been granted without adequate regulatory scrutiny, including assessments such as bioavailability/bioequivalence and stability studies.The absence of these assessments could compromise the quality, safety and efficacy of medicines. Substandard or ineffective antimicrobials could also contribute to the development and spread of drug-resistant infections.The Ministry has noted that antimicrobial resistance (AMR) is a major global public health concern requiring coordinated action. The G20 New Delhi Leaders’ Declaration had also underscored the need to address the challenge through a One Health approach.In a separate draft notification, the Ministry has proposed regulatory flexibility for manufacturers of medicinal gases, empty gelatin capsules and disinfectant fluids by allowing exemptions from certain provisions of the revised Schedule M.The matter was examined by the Drugs Technical Advisory Board (DTAB) at its 93rd meeting on February 16. The Board observed that some requirements under the revised Schedule M might not be relevant to the manufacturing processes of these products. It recommended continuing the exemptions available to these categories under the earlier Schedule M.The proposed amendment would allow Licensing Authorities to take product-specific decisions based on scientific and practical considerations.The Ministry has maintained that the proposed flexibility would neither dilute quality and safety standards nor weaken regulatory oversight. Instead, it is intended to align regulatory requirements with the specific nature and manufacturing processes of these product categories.

HTML tutorial

Tags :

Search

Popular Posts


Useful Links

Selected menu has been deleted. Please select the another existing nav menu.

Recent Posts

©2025 – All Right Reserved. Designed and Developed by JATTVIBE.